AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$21.65
+$0.02 (+0.09%) 4:00 PM ET
After hours$21.33
−$0.32 (−1.50%) 6:39 PM ET
Prev closePrevC$21.63
OpenOpen$21.67
Day highHigh$21.76
Day lowLow$21.63
VolumeVol13,345,880
Avg volAvgVol2,595,952
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
FY Revenue
$248.52M
EPS
0.00
Gross Margin
94.91%
Sector
Healthcare
AI report sections
MIXED
AVDL
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals shows strong medium- to long-horizon price performance and constructive technical positioning near the upper end of its 52-week range. Fundamentals indicate rapid revenue and earnings improvement with positive operating cash flow and a healthy current ratio, offset by very slim operating profitability and slightly negative net margin. Short interest and recent news flow appear moderate and largely neutral, while ongoing merger-related legal reviews introduce transaction and regulatory process uncertainty.
AI summarized at 3:33 AM ET, 2025-12-20
AI summary scores
INTRADAY:63SWING:76LONG:79
Volume vs average
Intraday (cumulative)
+596% (Above avg)
Vol/Avg: 6.96×
RSI
55.38(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: -0.01 Signal: -0.01
Short-Term
+0.02 (Strong)
MACD: 0.00 Signal: -0.02
Long-Term
+0.04 (Strong)
MACD: -0.19 Signal: -0.23
Intraday trend score
70.20
LOW70.20HIGH70.20
Latest news
AVDL•12 articles•Positive: 5Neutral: 7Negative: 0
NeutralBenzinga• Globe Newswire
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
The Irish High Court has sanctioned Avadel Pharmaceuticals' scheme of arrangement without modification, allowing Alkermes to acquire Avadel's entire issued share capital. The transaction is expected to close on February 12, 2026, with trading of Avadel shares on Nasdaq halting on February 11, 2026.
AVDLALKScourt sanctionscheme of arrangementacquisitionmergerIrish High CourtNasdaq delisting
Sentiment note
The court sanction is a procedural milestone that was expected and required for deal completion. While it represents progress toward closing, it is a neutral event as it was anticipated and does not indicate positive or negative business developments for the company itself.
NeutralGlobeNewswire Inc.• Na
Form 8.3 - Avadel Pharmaceuticals plc
State Street Global Advisors & Affiliates disclosed a purchase of 621 ordinary shares in Avadel Pharmaceuticals plc on January 15, 2026, bringing their total holding to 2,298,069 shares representing 2.36% of the company. The disclosure was filed under Irish Takeover Panel Rule 8.3.
AVDLState Street Global AdvisorsAvadel Pharmaceuticalsshare purchasestake increaseIrish Takeover PanelForm 8.3 disclosure
Sentiment note
The disclosure represents a routine regulatory filing of a share purchase by a major institutional investor. While the purchase indicates continued confidence in the company, the transaction size is relatively modest (621 shares) and the disclosure itself is a standard regulatory requirement rather than a significant strategic announcement. No material business developments or material changes are indicated.
PositiveBenzinga• Globe Newswire
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc through a scheme of arrangement. The approval was overwhelming, with 97.41% of votes cast in favor at the scheme meeting and 96.53% approval at the extraordinary general meeting. The transaction is expected to proceed pending satisfaction of remaining conditions.
AVDLALKSacquisitionshareholder approvalscheme of arrangementM&AIrish Companies ActLUMRYZ
Sentiment note
Shareholders overwhelmingly approved the acquisition with 97.41% voting in favor at the scheme meeting, indicating strong stakeholder support for the transaction. The company's commercial product LUMRYZ is highlighted as a differentiated therapy in the narcolepsy market.
NeutralGlobeNewswire Inc.• Na
Form 8.3 - Avadel Pharmaceuticals plc
State Street Global Advisors & Affiliates disclosed a dealing in Avadel Pharmaceuticals plc on December 23, 2025, purchasing 2,433 shares at $21.54 per unit while selling 263 shares at the same price. The entity now holds 2,292,882 shares representing 2.35% of the company's ordinary shares.
AVDLState Street Global AdvisorsAvadel Pharmaceuticalsshare purchasestake increaseForm 8.3 disclosureIrish Takeover Panel
Sentiment note
The disclosure itself is a regulatory filing with no inherent positive or negative implications. While the increased stake by a major institutional investor could be viewed positively, the form is purely informational and does not contain company-specific news or developments.
NeutralGlobeNewswire Inc.• Halper Sadeh Llc
Halper Sadeh LLC Encourages AVDL, CMA, KVUE Shareholders to Contact the Firm to Discuss Their Rights
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in merger and acquisition transactions.
AVDLCMACMAPBKVUEsecurities lawmergersacquisitionsshareholder rights
Sentiment note
Potential sale to Alkermes plc being investigated, no clear negative or positive indication
NeutralBenzinga• Globe Newswire
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
Avadel Pharmaceuticals announced the mailing of a proxy statement regarding its proposed acquisition by Alkermes, with scheme and extraordinary general meetings scheduled for January 12, 2026, to vote on the transaction.
Company is being acquired, which represents a significant corporate transition without clear positive or negative implications for the company's future
PositiveBenzinga• Juan Monteverde
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-DENN, ELST, AVDL, and CADE
Law firm Monteverde & Associates is investigating merger transactions for Denny's, Electronic Systems Technology, Avadel Pharmaceuticals, and Cadence Bank, offering shareholders potential legal recourse.
Sale to Alkermes includes potential additional $1.50 per share contingent value right pending FDA approval
PositiveGlobeNewswire Inc.• Halper Sadeh Llc
Halper Sadeh LLC Encourages HFWA, FITB, AVDL, BRNS Shareholders to Contact the Firm to Discuss Their Rights
Law firm investigating potential securities law violations and fiduciary duty breaches for several companies involved in mergers and acquisitions.
HFWAFITBFITBIFITBOmergersacquisitionssecurities lawshareholder rights
Sentiment note
Sale to Alkermes with potential additional cash payment per share contingent on FDA approval
PositiveBenzinga• Globe Newswire
Avadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal"
Avadel Pharmaceuticals received an unsolicited acquisition proposal from Lundbeck valuing the company at up to $23.00 per share, which the board has deemed a 'Company Superior Proposal' to the existing Alkermes transaction agreement.
Lundbeck made an unsolicited $23 per share proposal to acquire Avadel, potentially disrupting Alkermes' existing $2 billion acquisition agreement. Avadel's board is considering the proposal but has not yet withdrawn support for the Alkermes deal.
Stock price increased 20% due to higher buyout proposal, creating potential value for shareholders
NeutralBenzinga• Globe Newswire
Avadel Receives Unsolicited Proposal from Lundbeck
Pharmaceutical company Avadel received an unsolicited acquisition proposal from Lundbeck for $23.00 per share, which the Avadel Board believes could potentially be a 'Company Superior Proposal' to their existing agreement with Alkermes.
Currently evaluating an unsolicited proposal while maintaining existing merger agreement, indicating strategic consideration without definitive commitment
NeutralGlobeNewswire Inc.• Avadel Pharmaceuticals
Avadel Receives Unsolicited Proposal from Lundbeck
Avadel's Board of Directors received an unsolicited proposal from Lundbeck to acquire the company for up to $23.00 per share, which the Board believes could potentially result in a 'Company Superior Proposal' to its existing agreement with Alkermes.
Company is evaluating a new proposal while maintaining its current merger agreement, indicating a cautious and strategic approach
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
